KUAN-YIN LINMING-JU HSIEHSUI-YUAN CHANGIeong, Si-ManSi-ManIeongCheng, Chien-YuChien-YuChengWANG-HUEI SHENGSHAN-CHWEN CHANG2022-10-242022-10-242022-08-310929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/623944Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality. We aimed to evaluate the effect of immune dysfunction on immunogenicity of homologous and heterologous prime-boost COVID-19 vaccination.enAutoimmune disease; Immunocompromised; Non-steroidal anti-inflammatory drug; Serologic response; mRNA vaccine[SDGs]SDG3journal article10.1016/j.jfma.2022.08.017360894712-s2.0-85137740791https://api.elsevier.com/content/abstract/scopus_id/85137740791